This webinar, brought to you by Qiagen, will be hosted live and available on-demand.
Thursday, October 8th, 2026
1:00 - 2:00 PM ET
Measurable residual disease (MRD) provides important insight into disease persistence and recurrence risk in acute myeloid leukemia (AML), but molecular approaches to MRD assessment differ in their sensitivity, breadth, and practical applications. Understanding the strengths and limitations of available technologies can help researchers select appropriate methods for detecting disease-associated biomarkers and investigating treatment response.
In this webinar, brought to you by QIAGEN, Laura Dillon, will examine the evolving molecular landscape for MRD assessment in AML. Drawing on findings from the Pre-MEASURE study series, Dillon will discuss the use of next-generation sequencing (NGS) and digital PCR (dPCR) for sensitive MRD detection in patients undergoing bone marrow transplantation in complete remission. She will compare practical considerations surrounding these technologies and discuss their complementary value in research and clinical settings before examining emerging whole-genome sequencing (WGS)-informed strategies for MRD target identification.
Topics to be covered
- Explore the current molecular landscape for measurable residual disease assessment in acute myeloid leukemia
- Compare next-generation sequencing and digital PCR approaches for sensitive MRD detection
- Consider differences in sensitivity, breadth of detection, and application when selecting molecular methods
- Examine emerging whole-genome sequencing-informed approaches for identifying MRD targets
 | Laura Dillon, PhD, FACMG |
